Daclatasvir for the treatment of chronic hepatitis C virus infection.
Zelalem Temesgen, Stacey A. Rizza
págs. 277-288
Faldaprevir for the treatment of hepatitis C.
D. Campagna, S Demma
págs. 289-302
Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
M. N. El Gamal, P Andreone
págs. 303-314
Current treatment and future prospects of dopa-induced dyskinesias.
S Mazzucchi, D Frosini, U. Bonuccelli, R. Ceravolo
págs. 315-330
A report from the American Association of Urology Annual Meeting 2015 (May 15-19 – New Orleans, Louisiana, USA).
Xavier Rabasseda
págs. 331-338
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: